ArticleCell biochemistry and biophysics2025
KPT-330, A New Candidate Drug for Targeting NOTCH1 Overexpression in T-cell Acute Lymphoblastic Leukemia, An In Vitro and Silico Study.
Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The interaction between NPMc+ and Orai1 induces abnormal calcium influx to facilitate leukemogenesis.The FEBS journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B and T-lymphoid cancers usually originate from lymphoid progenitor cells. T-cell ALL, a subtype of acute lymphoblastic leukemia (ALL), arises due to unlimited and abnormal growth of blast cells. KPT-330, also known as Selinexor, prevents the transport of mRNAs and proteins from the nucleus to the cytoplasm by inhibiting the XPO1 transporter protein. The study aims to explore the NOTCH1 gene as a novel therapeutic target of KPT-330 in T-cell ALL by targeting the XPO1 protein. mRNA expression of the NOTCH1 gene was significantly elevated in T-cell ALL patients. The IC50 value of KPT330 for the Jurkat cells was determined by cell viability assay. The effect of KPT-330 on NOTCH1 gene expression in Jurkat cells was evaluated after 24, 48, and 72 h intervals. KPT-330 significantly downregulated the NOTCH1 gene expression at all time points in a dose-dependent manner. The molecular docking results revealed a binding affinity of -8.8 kcal/mol and identified GLU-140, LEU-141, and SER-144 as the potential amino acids of XPO1 forming a hydrogen bond with KPT-330. In silico analysis suggested the interaction of KPT-330 with the RNA-based NES_1 (UGUAUUAUU), NES_2 (UGUAUUUUU), and NES_3 (UUGUA) motifs in the 3' UTR of NOTCH1 mRNA resulting in NOTCH1 inhibition. Based on the results of in vitro and in silico studies, it was suggested that KPT-330 could be an ideal candidate drug for treating T-cell ALL patients with NOTCH1 overexpression.
Indexed as
Identifiers
40216697What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.